Yes, DDR pathways are often targeted in cancer therapy. Inhibitors of PARP (poly ADP-ribose polymerase), a protein involved in single-strand break repair, are used to treat cancers with defective BRCA1/2. These therapies exploit the concept of synthetic lethality, where blocking two complementary pathways leads to cell death.